← All trials
NCT05724602
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2023
- Primary completion
- Jul 31, 2029
- Completion date
- Oct 31, 2029
- First posted
- Feb 13, 2023
- Last posted
- Dec 11, 2023
- Enrollment
- 230
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- Merck KGaACollaborator
- University of FlorenceStudy chair
- University of GroningenStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.